Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Neumora Therapeutics, Inc. | 160,000 | reported | 14 Feb 2024 | tx 3+255,000 |
| Aptinyx Inc. | 40,000 | reported | 26 May 2022 | tx 16+458,990−100,000 |
| AbbVie Inc. | 16,623 | reported | 16 May 2022 | tx 101+1,105,302−780,016 |
| ACELYRIN, Inc. | 0 | reported | 21 May 2025 | tx 7+297,608−453,058 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 21 May 2025 | OTHER | ACELYRIN, Inc. | 50,000 | — | |
| 21 May 2025 | OTHER | ACELYRIN, Inc. | 92,158 | — | deriv |
| 21 May 2025 | OTHER | ACELYRIN, Inc. | 155,450 | — | deriv |
| 07 Jun 2024 | GRANT_AWARD | ACELYRIN, Inc. | 92,158 | 0.00 USD | deriv |
| 14 Feb 2024 | GRANT_AWARD | Neumora Therapeutics, Inc. | 80,000 | 0.00 USD | |
| 14 Feb 2024 | GRANT_AWARD | Neumora Therapeutics, Inc. | 160,000 | 0.00 USD | deriv |
| 19 Sept 2023 | PURCHASE | Neumora Therapeutics, Inc. | 15,000 | 12.62 USD | |
| 09 May 2023 | PURCHASE | ACELYRIN, Inc. | 50,000 | 18.00 USD | first after silence |
| 09 May 2023 | OTHER | ACELYRIN, Inc. | 155,450 | 0.00 USD | deriv |
| 09 May 2023 | OTHER | ACELYRIN, Inc. | 155,450 | 0.00 USD | deriv |
| 26 May 2022 | GRANT_AWARD | Aptinyx Inc. | 40,000 | 0.00 USD | deriv |
| 16 May 2022 | EXERCISE | AbbVie Inc. | 83,960 | 54.86 USD | |
| 16 May 2022 | SALE | AbbVie Inc. | 83,960 | 155.00 USD | |
| 16 May 2022 | EXERCISE | AbbVie Inc. | 83,960 | 54.86 USD | deriv |
| 01 Mar 2022 | SALE | AbbVie Inc. | 15,733 | 146.81 USD | |
| 01 Mar 2022 | SALE | AbbVie Inc. | 5,167 | 147.60 USD | |
| 01 Mar 2022 | SALE | AbbVie Inc. | 4,000 | 148.71 USD | |
| 01 Mar 2022 | SALE | AbbVie Inc. | 100 | 149.38 USD | |
| 01 Mar 2022 | SALE | AbbVie Inc. | 5,596 | 147.54 USD | |
| 01 Mar 2022 | SALE | AbbVie Inc. | 8,303 | 148.62 USD | |
| 01 Mar 2022 | SALE | AbbVie Inc. | 1,101 | 149.14 USD | |
| 25 Feb 2022 | TAX_WITHHOLDING | AbbVie Inc. | 30,156 | 149.54 USD | |
| 17 Feb 2022 | GRANT_AWARD | AbbVie Inc. | 7,972 | 0.00 USD | |
| 17 Feb 2022 | GRANT_AWARD | AbbVie Inc. | 14,722 | 0.00 USD | |
| 17 Feb 2022 | GRANT_AWARD | AbbVie Inc. | 36,673 | 0.00 USD |
1 purchase reported after at least 12 months of silence — most recent on 09 May 2023.